ArticleCureus2025
Radiation Therapy for Primary Cutaneous Rosai-Dorfman Disease of the Face: A Case Report Resistant to Multiple Lines of Treatment and a Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rosai-Dorfman disease (RDD) is a rare subtype of sinus histiocytosis, with primary cutaneous RDD (PCRDD) being an even rarer form, characterized by cutaneous lesions without systemic involvement. PCRDD presents a significant diagnostic challenge and is often resistant to conventional therapies, including surgical resection, steroids, and chemotherapy. Currently, no established management guidelines exist for this condition. Radiation therapy is emerging as a promising treatment option, especially for refractory cases involving cosmetically sensitive or difficult-to-resect areas. This case report presents a patient with treatment-resistant PCRDD affecting the face, which was refractory to multiple therapeutic approaches, including chemotherapy. The patient achieved durable remission with radiation therapy at an 18-month follow-up, highlighting the efficacy of this modality in managing resistant PCRDD and the importance of a multidisciplinary approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.